These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 12500906)
1. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(47):1065-7. PubMed ID: 12500906 [TBL] [Abstract][Full Text] [Related]
2. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002. JAMA; 2003 Jan; 289(1):36-7. PubMed ID: 12515265 [No Abstract] [Full Text] [Related]
3. Liver transplantation and the use of KAVA: Case report. Becker MW; Lourençone EMS; De Mello AF; Branco A; Filho EMR; Blatt CR; Mallmann CA; Schneider M; Caregnato RCA; Blatt CR Phytomedicine; 2019 Mar; 56():21-26. PubMed ID: 30668342 [TBL] [Abstract][Full Text] [Related]
4. Risk of kava hepatotoxicity and the FDA consumer advisory. Teschke R; Schulze J JAMA; 2010 Nov; 304(19):2174-5. PubMed ID: 21081732 [No Abstract] [Full Text] [Related]
9. Another FDA warning: Kava supplements. Parkman CA Case Manager; 2002; 13(4):26-8. PubMed ID: 12131903 [No Abstract] [Full Text] [Related]
10. Final report on the safety assessment of Piper methysticum leaf/root/stem extract and Piper methysticum root extract. Robinson V; Bergfeld WF; Belsito DV; Klaassen CD; Marks JG; Shank RC; Slaga TJ; Snyder PW; ; Andersen FA Int J Toxicol; 2009; 28(6 Suppl):175S-88S. PubMed ID: 19966149 [TBL] [Abstract][Full Text] [Related]
11. The Role of Adverse Event Reporting in the FDA Response to a Multistate Outbreak of Liver Disease Associated with a Dietary Supplement. Klontz KC; DeBeck HJ; LeBlanc P; Mogen KM; Wolpert BJ; Sabo JL; Salter M; Seelman SL; Lance SE; Monahan C; Steigman DS; Gensheimer K Public Health Rep; 2015; 130(5):526-32. PubMed ID: 26327730 [TBL] [Abstract][Full Text] [Related]
13. Kava extract, an herbal alternative for anxiety relief, potentiates acetaminophen-induced cytotoxicity in rat hepatic cells. Yang X; Salminen WF Phytomedicine; 2011 May; 18(7):592-600. PubMed ID: 21397479 [TBL] [Abstract][Full Text] [Related]
14. Kava hepatotoxicity: a European view. Teschke R; Schwarzenboeck A; Akinci A N Z Med J; 2008 Oct; 121(1283):90-8. PubMed ID: 18841189 [TBL] [Abstract][Full Text] [Related]
15. Kava: a supplement to avoid. Consum Rep; 2003 Mar; 68(3):8. PubMed ID: 12599340 [No Abstract] [Full Text] [Related]
16. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Estes JD; Stolpman D; Olyaei A; Corless CL; Ham JM; Schwartz JM; Orloff SL Arch Surg; 2003 Aug; 138(8):852-8. PubMed ID: 12912743 [TBL] [Abstract][Full Text] [Related]